Impact Partnership Wealth LLC Acquires Shares of 9,134 Merck & Co., Inc. (NYSE:MRK)

Impact Partnership Wealth LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 9,134 shares of the company’s stock, valued at approximately $1,037,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of MRK. Itau Unibanco Holding S.A. acquired a new position in Merck & Co., Inc. during the 2nd quarter valued at approximately $39,000. Abich Financial Wealth Management LLC grew its position in shares of Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after acquiring an additional 179 shares during the last quarter. Quarry LP bought a new position in Merck & Co., Inc. in the 2nd quarter worth approximately $42,000. Ruedi Wealth Management Inc. increased its position in shares of Merck & Co., Inc. by 27.7% during the 2nd quarter. Ruedi Wealth Management Inc. now owns 397 shares of the company’s stock valued at $49,000 after purchasing an additional 86 shares during the period. Finally, Dixon Mitchell Investment Counsel Inc. bought a new position in Merck & Co., Inc. during the first quarter valued at about $53,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $132.00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th. Sanford C. Bernstein assumed coverage on Merck & Co., Inc. in a research note on Thursday, October 17th. They set a “market perform” rating and a $115.00 price objective for the company. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 31st. Barclays reduced their price objective on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, October 7th. Finally, Truist Financial reduced their price objective on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $131.62.

Merck & Co., Inc. Stock Up 0.1 %

MRK traded up $0.11 during trading on Thursday, reaching $106.49. 395,256 shares of the stock traded hands, compared to its average volume of 8,753,088. The stock has a market cap of $269.72 billion, a price-to-earnings ratio of 118.20, a price-to-earnings-growth ratio of 1.55 and a beta of 0.39. Merck & Co., Inc. has a fifty-two week low of $99.80 and a fifty-two week high of $134.63. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22. The stock’s 50-day simple moving average is $113.86 and its two-hundred day simple moving average is $121.93.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 30th. The company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.12. The firm had revenue of $16.10 billion during the quarter, compared to analysts’ expectations of $15.87 billion. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter last year, the firm earned ($2.06) earnings per share. As a group, equities research analysts expect that Merck & Co., Inc. will post 7.88 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.